Sand Hill Global Advisors LLC Has $3.76 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Posted by Defense World Staff on Sep 9th, 2023

Sand Hill Global Advisors LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 9.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,601 shares of the company’s stock after buying an additional 1,910 shares during the period. Sand Hill Global Advisors LLC’s holdings in Zoetis were worth $3,762,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Aspire Private Capital LLC acquired a new stake in Zoetis in the 1st quarter valued at about $15,019,213,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the last quarter. VitalStone Financial LLC acquired a new stake in Zoetis in the 1st quarter valued at about $37,000. Worth Asset Management LLC acquired a new stake in Zoetis in the 1st quarter valued at about $26,000. Finally, HHM Wealth Advisors LLC lifted its stake in Zoetis by 1,160.0% in the 1st quarter. HHM Wealth Advisors LLC now owns 189 shares of the company’s stock valued at $31,000 after purchasing an additional 174 shares during the last quarter. 89.47% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In related news, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total value of $2,339,610.00. Following the transaction, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $192.97, for a total value of $178,111.31. Following the sale, the executive vice president now owns 25,434 shares in the company, valued at $4,907,998.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares in the company, valued at approximately $10,230,034.71. The disclosure for this sale can be found here. Insiders have sold 15,102 shares of company stock valued at $2,741,661 over the last three months. 0.12% of the stock is owned by insiders.

Zoetis Stock Down 1.1 %

Shares of ZTS opened at $185.78 on Friday. Zoetis Inc. has a 12 month low of $124.15 and a 12 month high of $194.99. The firm’s 50 day moving average is $182.19 and its 200-day moving average is $174.61. The stock has a market capitalization of $85.52 billion, a PE ratio of 39.03, a P/E/G ratio of 3.01 and a beta of 0.78. The company has a current ratio of 3.50, a quick ratio of 1.97 and a debt-to-equity ratio of 1.42.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.10. The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.16 billion. Zoetis had a net margin of 26.92% and a return on equity of 52.02%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted $1.20 earnings per share. Equities research analysts forecast that Zoetis Inc. will post 5.42 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ZTS shares. HSBC started coverage on shares of Zoetis in a research note on Wednesday. They issued a “buy” rating and a $230.00 target price for the company. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 2nd. Piper Sandler increased their price target on shares of Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Monday, August 14th. Stifel Nicolaus increased their price target on shares of Zoetis from $195.00 to $205.00 and gave the company a “buy” rating in a report on Monday, August 28th. Finally, The Goldman Sachs Group increased their price target on shares of Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $225.13.

Get Our Latest Stock Analysis on ZTS

Zoetis Profile

(Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.